Stevens Capital Management LP Has $1.91 Million Stake in Bio-Rad Laboratories (BIO)

Stevens Capital Management LP lifted its position in Bio-Rad Laboratories (NYSE:BIO) by 30.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 7,655 shares of the medical research company’s stock after purchasing an additional 1,795 shares during the quarter. Stevens Capital Management LP’s holdings in Bio-Rad Laboratories were worth $1,914,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of BIO. American Century Companies Inc. grew its holdings in shares of Bio-Rad Laboratories by 18.4% in the 1st quarter. American Century Companies Inc. now owns 702,366 shares of the medical research company’s stock worth $175,648,000 after purchasing an additional 108,949 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Bio-Rad Laboratories by 112.3% in the 4th quarter. Millennium Management LLC now owns 180,002 shares of the medical research company’s stock worth $42,961,000 after purchasing an additional 95,235 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Bio-Rad Laboratories by 16.7% in the 4th quarter. Wells Fargo & Company MN now owns 625,032 shares of the medical research company’s stock worth $149,175,000 after purchasing an additional 89,347 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Bio-Rad Laboratories by 5.0% in the 4th quarter. BlackRock Inc. now owns 1,776,710 shares of the medical research company’s stock worth $424,046,000 after purchasing an additional 85,176 shares during the last quarter. Finally, Monarch Partners Asset Management LLC bought a new stake in shares of Bio-Rad Laboratories in the 1st quarter worth about $17,861,000. 65.55% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts have recently weighed in on BIO shares. ValuEngine raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Jefferies Group upped their target price on shares of Bio-Rad Laboratories to $325.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Citigroup upped their target price on shares of Bio-Rad Laboratories to $325.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. CL King lowered shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating in a report on Friday, February 16th. Finally, Wells Fargo upped their target price on shares of Bio-Rad Laboratories from $280.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, March 20th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $297.20.

Shares of NYSE BIO opened at $291.66 on Friday. The stock has a market cap of $8.69 billion, a P/E ratio of 70.11, a P/E/G ratio of 3.17 and a beta of 0.95. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.99 and a current ratio of 4.33. Bio-Rad Laboratories has a 12-month low of $208.95 and a 12-month high of $293.43.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Tuesday, February 27th. The medical research company reported $1.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.28 by $0.22. The business had revenue of $620.43 million for the quarter, compared to the consensus estimate of $618.89 million. Bio-Rad Laboratories had a net margin of 34.32% and a return on equity of 3.84%. sell-side analysts forecast that Bio-Rad Laboratories will post 6.13 earnings per share for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply